CANCER-ID was a European consortium funded by the Innovative Medicines Initiative (IMI) aimed at the establishment of standard protocols for and clinical validation of blood-based biomarkers. It brought together experts from academic and clinical research, innovative Small-to-Medium sized Enterprises (SMEs), diagnostics companies and the pharmaceutical industry thus providing a unique setting for establishing clinical utility of liquid biopsies . About ANGLE plc www.angleplc.com ANGLE is a world leading liquid biopsy company with sample-to-answer solutions. ANGLE s proven patent protected platforms include a circulating tumor cell (CTC) harvesting technology and a downstream analysis system for cost effective, highly multiplexed analysis of nucleic acids and proteins.
Angle PLC - Parsortix Demonstrates High Capture Rate of CTCs saltlakecitysun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from saltlakecitysun.com Daily Mail and Mail on Sunday newspapers.
ANGLE plc: Angle PLC - Parsortix Demonstrates High Capture Rate of CTCs
Parsortix system demonstrates high capture rate of CTCs irrespective of biomarker status or phenotype
GUILDFORD, SURREY / ACCESSWIRE / January 29, 2021 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company, is pleased to announce the publication of a five year programme of work undertaken by the CANCER-ID Consortium to establish the performance and technical capabilities of five circulating tumour cell (CTC) isolation platforms, in which key advantages of the Parsortix
® system were identified. The CANCER-ID consortium is supported by Europe s Innovative Medicines Initiative (IMI) and is a Europe-wide Public-Private-Partnership aimed at the establishment of standard protocols for, and clinical validation of, blood-based biomarkers in order to drive wide adoption of liquid biopsy in clinical practice and pharma services.
(1)
NIJMEGEN, Netherlands, Jan. 28, 2021 /PRNewswire/
To take AI development in pathology to the next level, a European consortium combining leading European research centres, hospitals as well as major pharmaceutical industries, is going to develop a repository for the sharing of pathology data. The 6-year, €70 million project called BIGPICTURE, will herald a new era in pathology.
Background: Sectra contributes to accelerate AI innovation for diagnostics in digital pathology
Sectra engages in the new EU Innovative Medicines Initiative project BIGPICTURE to construct a large-scale database of pathology images. Sectra s contributions will help accelerate the development of improved diagnostic methods based on artificial intelligence, supporting an effective interplay between healthcare and academic research. The Sectra efforts include a close collaboration with the BIGPICTURE partners Center for Medical Image Science and Visualization (CMIV) at Linköping University and Regio